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A novel tumor-associated protein, termed 90K, and recognized by mAb SP-2 was purified from serum of breast cancer patients, ovarian cancer 
a&tic fluid and conditioned medium of human breast cancer cells. In these three sources, native 90K is present as a high molecular weight complex 
that was dissociated by SDS-PAGE into a major band of approximately 90,000 Da. On the basis of electrophoretic mobility, buoyant density value, 
amino acid composition, and immunoreactivity, the 90K from the different sources appeared to be identical. NH*-terminal amino acid sequence 
revealed no homology to known protein. 
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1. INTRODUCTION 
Various proteins which are shed or secreted by tumor 
cells had been previously identified in the serum of pa- 
tients with different forms of cancers. These proteins 
can be used as diagnostic-prognostic indicators and for 
therapy surveillance. To obtain mAbs against circulat- 
ing breast cancer-associated antigens, mice were immu- 
nized with a mixture of proteins released into condi- 
tioned medium of CG-5 human breast cancer cells [l]. 
One of the mAbs generated, SP-2, recognized an antigen 
of molecular weight 90,000, termed 90K. This protein 
was found in more than 80% of breast cancers but not 
in non-cancerous normal mammary gland surrounding 
the cancer tissue [l]. Quantitation of 90K protein in the 
serum has been made possible by development of an 
ELISA assay with SP-2 mAbs [2]. Approximately 50% 
of patients with breast cancer, 40% of patients with 
gastrointestinal malignancies, and 30% of patients with 
gynecological malignancies, had elevated serum levels 
of the 90K protein [2]. More importantly, the assay has 
demonstrated that the fraction of patients showing ele- 
vated serum levels is greater for individuals with meta- 
static disease and that the level of 90K in serum corre- 
lates with cancer progression [2-4]. Since 90K protein 
is distinct from other circulating antigens such as CA 
15-3, CEA, and CA 125 [2,4], it may represent an addi- 
tional useful diagnostic tool for the surveillance of 
breast cancers and other malignant diseases. 
The 90K protein has not yet been characterized, so 
it is not known if it has previously been described under 
a different name or it is a new undiscovered entity. In 
this report, we describe the purification and characteri- 
zation of SP-2-reactive 90K protein from conditioned 
medium of CG-5 cells, breast cancer patient serum, and 
ovarian cancer patient ascitic fluid. 
2. MATERIALS AND METHODS 
CG-5, an estrogen-supersensitive ariant of the MCF-7 human 
breast cancer cell line. was previously described [5]. The other human 
breast cancer cell lines are from The American Tissue Culture Collec- 
tion. The murine mAb SP-2 produced by hybridomas grown in pris- 
tane-primed Balblc mice [l] was purified from ascitic fluid by ammo- 
nium sulfate precipitation followed by ion-exchange chromatography 
[2]. Purified SP-2 was labeled with sodium-? using lactoperoxidase 
[6]. The proteases and other enzymes were purchased from Sigma. 
Electrophoresis reagents were from Bio-Rad Laboratories. All other 
reagents were of the highest commercially available grade. 
2.1. Solid-phase radioimmunoassay 
A ‘two-step’ sandwich IRMA was developed to quantitate 90K. The 
assay uses polystyrene beads coated with mAb SP-2 as solid phase and 
‘*‘I-SP-2 as the labeled antibody. Results are expressed in arbitrary 
units. The detailed procedure is described elsewhere [7]. 
2.2. PAGE and immune blotting analyses 
Correspondence address: S. Iacobelli, Cattedra Oncologia Medica, 
Universita degli Studi ‘G. D’Annunzio’, Chieti, Italy. 
Abbreviations: BSA, bovine serum albumin; ELISA, enzyme-linked 
immunosorbent assay; IRMA, immunoradiometric assay; mAb, mon- 
oclonal antibody; NP-40, Nonidet P-40; PAGE, polyacrylamide gel 
electrophoresis; PBS, phosphate-buffered saline; SDS, sodium do- 
decyl sulfate. 
SDS-PAGE was performed according to [8]. Samples were heated 
at 50°C for 30 min in the presence of sample buffer (63 mM Tris-HCI, 
pH 6.8,4% SDS, 5% mercaptoethanol and 20% glycerol) and electro- 
phoresed for 4 h at 40 mA. A 9% separating el and a 4% stacking 
gel were used. The separating el was silver stained using a Bio-Rad 
kit. Native PAGE was performed on 420% gradient gel for 16 h at 
20 mA. Sample buffer was 63 mM Tris-HCl plus 0.25% NP-40. The 
gel was either silver stained or electroblotted onto nitrocellulose mem- 
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branes at 50 V for 2 h as described by Towbin et al. [9]. except that 
the transfer buffer did not contain methanol. The membranes were 
blocked with bovine skim milk, followed by incubation with mAb SP-2 
(10 &ml) for 2 h at room temperature. The membranes were washed 
thoroughly with PBS and stained with avidin-biotin staining kit 
(Sigma) accordmg to the manufacturer’s instructions. 
2.3. Radrolabeling of cells and immunoprecipitatlon 
For metabolic labeling, 2 x lo6 cells were incubated at 37°C for 6 
h in Dulbecco modified Eagle’s medium containing 250 &i/ml 
[“S]methiomne. Culture fluids containing the radioactive proteins and 
pre-clarified as described [l], were incubated with one SP-2-coated 
polystyrene bead at 4°C for 16 h. The beads were washed with distilled 
water, treated with 100 ~1 of SDS-sample buffer during 30 min at 
50°C. Extracts were analysed by SDS-PAGE. As controls, ahquots of 
culture fluid were incubated with polystyrene beads that have been 
coated with a mAb against alpha-fetoprotein. [?S]methionine-labeled 
protein bands were visualized by fluorography. In certain experi- 
ments, the cells were incubated m the presence of 5 pg/ml tunicamycin 
(Sigma) for 2 h prior to the addition of [‘5S]methionine. 
2.4. Purljcation of 90K protein 
(a) From conditronedmedium. CG-5 cells were grown in Dulbecco’s 
modified Eagle’s medium supplemented with 3% FCS using Cell Fac- 
tory plastic chambers (Nunc. Rosktlde, Denmark). Conditioned me- 
dium from confluent cell layers was collected. Then fresh medium was 
added and collected after 24 h incubation periods for additional 34 
days. The concentration of 90K protein produced under these condi- 
tions ranged from 100 to 400 U/ml. Pooled culture supernatants (10 
1) were centrifuged at 4.000 x g followed by a IO-fold concentration 
using a Minitan apparatus (Millipore). Solid ammonium sulfate was 
slowly added (final concentration 43%) and allowed to stand overnight 
at 4°C. protein precipitates were collected by centrifugation at 
10,000 x g. The precipitates were stored at -20°C. Under these condi- 
tions the immunoprecipitation of 90K activity by SP-2 antibody is 
stable for at least 2 months. 
(b) From human serum. Serum from a patient with advanced breast 
cancer containing high concentrations of 90K protein as revealed by 
IRMA analysis was cleared by centrifugation at 10.000 x g for 20 min. 
then diluted I: I with PBS and precipitated with ammonium sulfate as 
described above. 
(c) From ascitic fluid. Ascitic fluid was obtained by paracentesis 
from a patient with advanced ovarian carcinoma. The fluid was 
cleared by centrifugation at 10,000 x g for 20 min and precipitated 
with ammonium sulfate as described. 
The ammonium sulfate precipitates were dialyzed extensively 
against PBS and poured into a Sepharose CL-6B column (4.2 x 85 cm) 
equilibrated and eluted with PBS plus 0.5 M NaCl, pH 8.1. at a flow 
rate of 18 ml/h. Fractions (5 ml) were collected and assayed for 90K 
protein by IRMA analysis. Fractions containing 90K protein were 
pooled, dialyzed against 0.005 M Na-phosphate buffer, pH 7.4, and 
applied to a DE 52-cellulose column (2 x 8 cm) equilibrated in the 
same buffer. The column was washed extensively with buffer and the 
absorbed proteins were eluted using a stepwise sodium chloride gradi- 
ent (0.062 to 1.0 M). Fractions containing the 90K protein activity 
were pooled and mixed with SP-2 antibody conjugated to Sepharose 
CL4B (4 mg antibody/ml resin) at a volume ratio of 8:l (sample/ 
resin), mAb SP-2 was coupled to Sepharose by the method of Schnet- 
der et al. [lo]. The mixture was mixed overnight at 4°C and the 90K 
protein was eluted with 3 M MgQ. The amount of protein was 
estimated with the Bio-Rad protein assay based on the method of 
Bradford [l 11. 
2.5. Density gradient centrifugation 
Centrifugation of the 90K protein isolated from either CG-5-condi- 
tioned medium, breast cancer serum, or ovartan cancer ascitic fluid 
after desorption from the immuno affinity matrix, was performed in 
5 ml of CsCl isopicnic density gradient. The protein was dissolved m 
a CsCl solution in PBS with a startmg density of 1.4 g/ml. and the 
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gradients were formed by centrifugation in a Beckman SW 50.1 rotor 
at 145,000 x g for 72 h at 4°C. Fractions (0.25 ml) were collected, 
diluted I:10 with PBS and assayed for antigenic activity by IRMA. 
The density of each fraction was determined by weighing a known 
volume. 
2.6. Biochemical characterization of the 90K protein 
The 90K protein was applied on microtiter plates. Microplates 
(Dynatecs) were coated with 50 ~1 of purified protein (100 ng/ml of 
0.05 M carbonate buffer, pH 9.6) and incubated overnight. 
(a) Chemical treatment. Methanol treatment was carried out at 4°C 
for 30 min. Denaturation was performed with either 6 M urea and 6 
M guanidine-HC1 or 1% SDS at 45°C for 1 h. Periodate oxidation was 
accomplished for 1 h at room temperature with 10.20, 30,40, 50 mM 
NaIO, in acetate buffer (50 mM, pH 4.5) m the dark according to Stahl 
et al. [12]. Reduction was performed with dithiothreitol(l0 mM in 50 
mM Tris, pH 8.1) or 5% 2-mercaptoethanol at 37°C for 1 h. Alkyla- 
tion was performed with 20 mM iodacetic acid at 30°C for 30 mm. 
(b) Proteolytrc enzymes. Microplates were exposed at 37°C for 90 
mm to either trypsin (2 mg/ml), chymotrypsin (2 mg/ml), pronase (I 
mg/ml) in 50 mM Tris, 2 mM CaCI,, pH 8.1, or to papain (0.2 mg/ml) 
in 50 mM cysteine-HCI, pH 6.0. 
(c) E,~oglycosidases. Microplates were exposed to either neuram- 
inidase, fucosidase, or-glucosidase and,&glucosidase m 50 mM acetate 
buffer, pH 5.0. or to chondroitinase-ABC in 250 mM Tris, 176 mM 
CH,COONa, 250 mM NaCI, pH 8.0. Incubations were carried out at 
37OC for 90 min. Appropriate concentrations of exoglycostdases were 
chosen to ensure complete digestion of the oligosaccharide residues. 
This was verified in separate experiments in which the substrates were 
shown to be completely hydrolyzed as detected by thin-layer chroma- 
tography. 
After treatment, microplates were washed and treated with 1% 
gelatin in PBS and 50 ~1 of ‘251-labeled SP-2 (approximately 50,000 
cpm) were added to each well and incubated at 37°C for 1 h. After 
3 washes with PBS, the bound radioactivity was determined m a 
gamma-counter. 
2.7. Amino acid analysis and amino-terminal sequencing 
Purified 90K protein was electrophoresed in a 9% SDS poly- 
acrylamide gel under reducing conditions using a Mini-gel apparatus. 
Proteins were electroblotted to polyvinylidene difluoride membrane 
(Immobilon, Millipore Corp., Beaford, MA), stained with Coomassie 
blue. and the bands corresponding to an M, of 90 kDa excised. For 
ammo acid analysis, 3-1 bands for a total of approximately 50 pg of 
90K were hydrolyzed under vacuum in 6 N HCI at 110°C for 22 h. 
After hydrolysis, the amino acids were analyzed on a Beckman ana- 
lyzer using a pH gradient system [ 131. For amino-terminal sequencing. 
approximately 20-30 pg of protein were subjected to mtcrosequence 
analysis utilizing a pulsed liquid sequencer (Applied Biosystems Inc., 
Mod. 475). 
3. RESULTS 
The purification procedure used for the isolation the 
90K protein from either conditioned medium of CG-5 
cells or from breast cancer patient serum, and ovarian 
cancer patient ascitic fluid is summarized in Table I. At 
each step of purification, the total amount of proteins 
was determined, and the amount of 90K protein was 
quantitated by an IRMA. Nearly all 90K protein immu- 
noactivity was recovered in a 43% ammonium sulfate 
precipitate, resulting in about 4-fold enrichment. This 
step removed the large majority of albumin present in 
the initial preparation. The ammonium sulfate-precipi- 
tated protein was next subjected to size exclusion 
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chromatography using a Sepharose CL-6B column 
(Fig. 1). The 90K protein from CG-5 cells, breast cancer 
serum, and ovarian cancer ascitic fluid was identified in 
a major peak eluting immediately behind the void vol- 
ume of the column, indicating that it is a high molecular 
weight complex. In a few experiments, a lower molecu- 
lar weight species probably representing a degradation 
product was also observed. Low molecular weight pro- 
teins found at the end of the elution were unreactive 
with the SP-2 antibody. Treatment of the samples with 
either 6M urea or 6M guanidine-HCl before chroma- 
tography gave identical elution profiles (not shown). 
The high molecular weight peak (corresponding to frac- 
tions 21-28 of Fig. 1) was further purified by DEAE- 
cellulose chromatography. The 90K protein obtained 
from each of the three different sources eluted from the 
column at a NaCl concentration of 0.25 M (data not 
shown). The final purification was accomplished by im- 
munoaffinity on Sepharose CL4B coupled with SP-2. 
Bound mAb was extracted with 3 M MgCl,. Other 
eluting solutions which were used including glycine-HCl 
(pH 2.4), 1 M NaOH (pH 11.2) and 3 M KSCN were 
less effective for protein elution. 
Based on specific activity (U/pg protein), the purifica- 
tion of 90K protein from CG-5 tissue culture fluid, 
breast cancer serum, and ovarian cancer ascitic fluid 
was approximately 84,300-, 52,300- and 83,400-fold, re- 
spectively. These enrichments were calculated by meas- 
uring the 90K immunoreactivity in the 3 M MgCl, ex- 
tracted from the affinity matrix with IRMA and deter- 
mining the amount of protein by comparing the silver- 
staining intensity of the 90K band on SDS-PAGE gels 
with BSA standards of known concentration. Starting 
from 50 ml of serum (about 3.5 g protein) from a breast 
cancer patient, approximately 13 pug of protein were 
Fraction 
Fig. 1. Sepharose CLdB column chromatography of 90K isolated 
from CG-5 tissue culture fluid (-), breast cancer patient serum (. .), 
and ovarian cancer patient ascitic fluid (--). Fractions were assayed for 
90K activity by IRMA. The arrow indicates the elution volume of 
Dextran blue 2000. 
recovered in the final purified preparation. Based on the 
purification and the calculated recovery, we estimate 
that the concentration of 90K protein in the serum of 
a breast cancer patient is approximately 1.5 pg/ml. 
3.1. PAGE and immunoblotting analyses of 90Kprotein 
isolated from different sources 
In agreement with previous data [l], 90K protein re- 
leased into the conditioned medium of [35S]methionine- 
labeled CG-5 cells and other breast cancer cell lines 
migrates as a single band with an apparent molecular 
weight 90 kDa as revealed by SDS-PAGE analysis (Fig. 
2A). The mobility of [35S]methionine-labeled protein 
was identical under reducing or non-reducing condi- 
tions, suggesting that the protein does not contain intra- 
Table I 
Purification of 90K 
Sample 
CG-5 tissue culture 
Fluid (10 I) 
(NH&SO, precipitate 
Sepharose CL-6B 
DEAE-cellulose 
Immunoaffinity 
Breast cancer serum 
(50 ml) 
(NH&SO, precipitate 
Sepharose CL-6B 
DEAE-cellulose 
Immunoaffinity 
Ovarian cancer 
Ascitic fluid (1 liter) 
(NH&SO, precipitate 
Sepharose CLdB 
DEAE-cellulose 
Immunoaffinity 
Protein Activity Yield 
(mg) (U x 10-6) (%) 
14,100 2.51 (100) 
3,700 2.61 (104) 
230 1.92 76.4 
61 1.71 68.1 
0.029 0.44 17.5 
3,100 1.28 (100) 
950 1.38 106 
58 0.91 71 
15 0.71 55.4 
0.013 0.28 21.8 
13,500 0.62 (100) 
4,250 0.71 114 
282 0.58 93.5 
282 0.58 93.5 
0.11 0.21 34 
Purification 
(1) 
4.0 
46.8 
157 
84,300 
(1) 
3.5 
38 
115 
52,277 
(1) 
3.6 
44.7 
44.7 
83,380 
Specific activity 
(Wg) 
0.18 
0.7 
8.3 
28 
15,174 
0.41 
1.4 
15.6 
47.3 
15,538 
45.9 
167 
2,056 
2,056 
19,090 
61 
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a b c 
c 
Fig. 2. PAGE and Western blot analysis of 90K. (A) Immunoprecipitates of radioactive 90K from human breast cancer cells. Aliquots (200,000 
trichloroacetic acid precipitable cpm) of [35S]methionine-labeled culture fluid were immunoprecipitated with mAb SP-2 (lanes a-e) or mAb against 
a-fetoprotein (lane f), and analyzed by SDS-PAGE in the presence (lanes a-c,e) or absence (lane d) of 2mercaptoethanol. followed by Auorography. 
Lanes a and d, CG-5 cells; lane b. MCF-7 cells; lane c, T47D cells; lane e, tissue culture thud from CC-5 cells after the cells were exposed to 
tunicamycin before (3”S]methionine labeling. (B) SDS-PAGE anaiysis of 90K purified from CC-5 culture fluid (lane a, 1,220 U), breast cancer patient 
serum (lane b, 1,550 U), and ovarian cancer patient a&tic fluid {lane c, 1,320 U). The gels were silver stained. (Cc) Western blot of purified 90K 
from CG-5 culture fluid (lane a), breast cancer serum (lane bk and ovarian cancer as&tic &rid (lane c). Purified 90K was analyzed on 4-20% gradient 
gel containing 0.1% NPAO and proteins electroblotted onto a nitroceltulose membrane. The arrowhead indicates migration of ferritin (‘l/c, = 450 
kDa). Positions of size markers are indicated with arrowheads m kDa. 
chain disulfide bonds. Moreover, tunicamycin treat- 
ment of CC-5 cells prior to labeling with [35S]methion- 
ine did not influence the electrophoretic mobility of the 
90K protein isolated from the conditianed medium 
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1.12 1.18 1.24 1.3 1.36 1.42 1.48 
Density (g/ml> 
Fig. 3. Density gradient centrifugation of 90K. Purified 90K from 
CG-5 culture tluid (-), breast cancer serum (...), ovarian cancer 
ascitic fluid (---), and unfractionated breast cancer serum (-.-) were 
subjected to equilibrium ultracentrifugation i cesium chloride. Frac- 
tions were assayed for 90K activity by IRMA, and density was deter- 
mined by weighting a known volume. Arrow, buoyant density of 
/I-galactosidase. 
(Fig. 2A, lane c). It appears therefore that the 90K 
protein does not contain detectable amounts of N- 
linked carbohydrates. Fig. 23 depicts a comparison of 
the electrophoretic mobility on SDS-PAGE of 90K pro- 
tein purified from CG-5 conditioned medium, breast 
cancer patient serum, and ovarian cancer patient ascitic 
fluid. This experiment shows that a protein with appar- 
ent molecular weight of 90,000 was detected in silver- 
stained gels. Co-electrophoresis of the purified protein 
from breast cancer patient serum detected by silver 
staining and [35S]methionine-labeled immunoprecipi- 
tates from CG-5-conditioned medium analyzed by au- 
toradiography gave a superimposable band with appar- 
ent molecular weight of 90,000 (data not shown). 
Immunoblot analysis of the purified 90K protein 
transferred from a native 420% polyacrylamide gel 
containing 0.25% NP-40, demonstrated the presence of 
similarly immunoreactive species in CG-5conditioned 
medium, breast cancer serum, and ovarian cancer as- 
citic fluid (Fig. 2C). The SP-2 antibody bound in these 
three sources to a high molecular weight (M, > 450 
kDa) diffuse band. The SP2 antibody poorly recognized 
the 90K polypeptide transferred from SDS-gels (data 
not shown). These results are consistent with the Sepha- 
rose CL-6B elution profiles shown in Fig. 1 and indicate 
that the native 90K protein isolated from different 
sources exists as a high molecular weight aggregate. 
3.2. Analysis of puriJied 90K by density gradient centrif- 
ugation 
Samples of protein eluted from SP-2 affinity matrix 
were subjected to density gradient centrifugation. This 
procedure did not reveal different average buoyant den- 
sity for the antigen obtained from the three different 
sources which ranged between 1.28 g/ml and 1.3 1 g/ml 
(Fig. 3). Moreover, the 90K protein in ~fractionated 
breast cancer serum produced essentially an identical 
density profile, indicating that 90K isolated by this pro- 
cedure did not represent a subset of the original antigen. 
3.3. Amino acid analysis and amino-terminal sequence of 
90K 
Table II shows that 90K protein purified from CG-5 
cells conditioned medium, breast cancer patient serum, 
and ovarian cancer patient ascitic fluid have similar 
amino acid composition. The antigen was relatively rich 
in glutamic acid/glutamine, in addition to serine and 
leucine. The NH~-te~inal sequence of 90K from the 
three different sources was determined for the first 22 
amino acids by automated Edman degradation (Table 
III). The repetitive yield during the sequencing was 
291%. A single amino acid sequence was found in all 
preparations. The sequence was compared with all pro- 
tein sequences in the GenebanWEMBL databases with 
the aid of the tFasta program. No significant homology 
with any known protein in the database was observed. 
The biochemical nature of the SP-2 determinant on 
90K proteins was investigated using several chemical 
and enzymatic treatments {Table IV). Exposure to 
methanol strongly reduced 90K immunoreactivity as 
did 6 M guanidine-HCl, 6 M urea or 1% SDS, lyophil- 
ization and heat. Neither reduction with dithiothreitol 
and 2-mercaptoethanol nor alkylation with iodoacet- 
amide or treatment with non-ionic detergents NP-40, 
Tween 20, and Triton X-100 affected the immunoreac- 
tivity of 90K protein. Exposure to sodium-m-periodate 
Table II 
Amino acid composition of 90K 
Amino acid Molar percentage 
CG-5 cells Breast cancer Ovarian cancer 
serum ascitic fluid 
Glx 11.8 10.7 Il.1 
Asx 7.6 6.9 8.3 
Ser 12.4 11.9 11.9 
Thr 4.3 4.8 4.3 
Gly 8.8 9.1 8.9 
Pro 5.1 4.9 4.7 
Val 4.9 4.2 5.1 
Leu 12.1 13.3 13.2 
Ile 1.1 0.9 1.3 
Ala 8.1 7.9 6.9 
Phe 2.8 2.4 2.5 
Met 1.1 1.3 0.9 
His 3.1 3.3 2.9 
Lys 2.5 2.1 2.8 
Arg 4.1 3.9 3.2 
Tyr 3.5 3.7 3.7 
Trp N.D. N.D. N.D. 
Cys N.D. N.D. N.D. 
N.D. = not dete~ined. 
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Table III 
Amino acid sequence of the NH,-terminal end of 90K from three 
sources 
CG-5 culture medium 
VNDGDM(C)LADGGATNQGRVEIF 
Breast cancer serum 
V(N)DGDMPLADGG(A)TNQGRVEIF 
Ovarian cancer ascitic fluid 
VNDGDM(C)LADGGATNQG(L)VEIF 
Sequence determined by Edman degradation as described in section 
2. Residues in parentheses are uncertain. 
had a small effect at high concentrations (50 mM). All 
the proteases tested reduced 90K immunoreactivity, the 
most effective were pronase and papain. Treatment with 
exoglycosidases did not affect 90K immunoreactivity. 
In fact, the ability of the immobilized antigen to bind 
“‘I-labeled SP-2 following treatment with neuram- 
inidase and ,L?-galactosidase, was increased suggesting 
that removal of terminal carbohydrate moieties may 
increase accessibility towards the SP-2 epitope on the 
90K protein. 
4. DISCUSSION 
mAb SP-2 specially binds to a 90 kDa protein which 
can be immunoprecipitated with this antibody from 
conditioned medium of breast cancer cells and from 
sera and ascitic fluid of tumor bearing patients. Native 
90K protein purified from conditioned medium, human 
breast cancer serum, and ascitic fluid from ovarian can- 
cer exists as a high molecular weight complex composed 
of several 90 kDa molecules. This suggests that in its 
native state this protein tends to form an oligomeric 
structure. The 90K protein isolated from either condi- 
tioned medium of CC-5 cells or breast cancer serum and 
ovarian cancer ascitic fluid all have similar behaviour 
when analysed by size-exclusion chromatography, ion- 
exchange chromatography, PAGE and immunoblotting 
analyses as well as buoyant density ultracentrifugation. 
Moreover, the 90K protein isolated from these three 
sources have similar amino acid composition and NH,- 
terminal amino acid sequence indicating that they are 
encoded by the same gene. It appears therefore that the 
90K protein isolated from either established long-term 
cancer cell lines, from cancer patients’s erum or ascites 
represent similar if not identical molecules. 
Various chemical and physical treatments of 90K 
protein were undertaken in order to shed light on the 
properties of this molecule. Denaturating agents or 
treatments greatly reduced antibody binding, further 
indicating that the SP-2 binds to a conformational de- 
terminant of the 90K protein. Furthermore, dissocia- 
tion of the oligomeric structure of the antigen into mon- 
omers under denaturating conditions resulted in a 
nearly complete loss of SP-2 binding activity. 
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Other tumor-associated antigens shown to be ex- 
pressed by breast cancers with apparent molecular 
weight of 90 kDa are likely to represent distinct mole- 
cules for the following reasons. The antigen recognized 
by mAb B6.2 [14,15] is a cell surface glycoprotein and 
contrary to 90K, is restricted to breast cancer cells. The 
antigen recognized by mAb 465.12s [161 is a cell surface 
glycoprotein. This glycoprotein is shed by the cells, and 
similarly to 90K can be isolated from the conditioned 
medium of cultured cells and from the serum of cancer 
patients. However, unlike the 90K this protein is an 
N-glycosylated glycoprotein [ 161. The melanoma-asso- 
ciated antigen termed ~97, gp87, or gp95 [17-191 is a 
membrane protein which is structurally related to trans- 
ferrin [20]. Another melanoma antigen, FD, is also a cell 
surface glycoprotein whose expression is restricted to a 
very limited number of cells [21]. Finally, the antigen 
defined by mAb 3G2-C6 [22] is a cell surface component 
expressed in a significant number of bladder cancers but 
rarely present in breast cancers [23]. 
In summary, this report describes the purification of 
Table IV 
Effects of chemical and physical treatments on 90K activity 
Treatment Relative binding activity 
Control 1 
Methanol 0.04 
Guanidine-HCl 6M 0.18 
Urea 6M 0.19 
SDS 0.14 
Dithiothreitol 0.89 
2-Mercaptoethanol 1.1 
Iodacetic acid 0.93 
NP-40 1.13 
Tween-20 1.05 
Triton X-100 0 88 
Lyophylization 
Heat (100°C 5 mm) 
0 
0 
Periodate concentration (mM) 
0 
10 
20 
30 
40 
50 
1 
1.05 
0.91 
0.95 
0.90 
0.71 
Proteases 
Pronase 
Papain 
Trypsin 
Chymotrypsm 
0.05 
0.07 
0.38 
0.42 
Exoglycosidases 
Neuraminidase 
Fucosidase 
Chondroitinase ABC 
a-Galactosidase 
/3-Galactosidase 
1.28 
0.98 
0.98 
0.98 
1.62 
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a 90K protein by a four-step procedure involving am- 
monium sulfate precipitation, size-exclusion chroma- 
tography, ion-exchange chromatography, and immu- 
noaffinity chromatography with SP-2 mAb. The degree 
of purity of the 90K protein is established by SDS- 
PAGE analysis and silver staining and by a unique 
amino terminal sequence. The availability of purified 
90K protein with information on partial amino acid 
sequence will facilitate cDNA cloning and detailed anal- 
ysis of expression in normal and various pathological 
tissues. 
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